[索拉非尼和舒尼替尼的皮肤副作用] - Suppr

Suppr

超能文献

[Cutaneous side effects of sorafenib and sunitinib].

作者信息

Autier J, Mateus C, Wechsler J, Spatz A, Robert C

机构信息

Service de dermatologie, institut Gustave-Roussy, 39, rue Camille-Desmoulins, 94805 Villejuif cedex, France.

出版信息

Ann Dermatol Venereol. 2008 Feb;135(2):148-53; quiz 147, 154. doi: 10.1016/j.annder.2007.12.006. Epub 2008 Feb 13.

DOI:10.1016/j.annder.2007.12.006

PMID:18342102

Abstract

摘要

相似文献

[Cutaneous side effects of sorafenib and sunitinib].

Ann Dermatol Venereol. 2008 Feb;135(2):148-53; quiz 147, 154. doi: 10.1016/j.annder.2007.12.006. Epub 2008 Feb 13.

A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.

J Natl Cancer Inst. 2008 Feb 20;100(4):282-4. doi: 10.1093/jnci/djm311. Epub 2008 Feb 12.

Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.

Br J Dermatol. 2009 Nov;161(5):1045-51. doi: 10.1111/j.1365-2133.2009.09290.x. Epub 2009 May 5.

[Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib].

Hautarzt. 2010 Aug;61(8):662-7. doi: 10.1007/s00105-010-1942-7.

Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.

Dermatol Ther. 2011 Jul-Aug;24(4):396-400. doi: 10.1111/j.1529-8019.2011.01435.x.

Risk of arterial thrombosis not increased by sorafenib or sunitinib.

J Clin Oncol. 2010 Oct 20;28(30):e619; author reply e620. doi: 10.1200/JCO.2010.31.0219. Epub 2010 Aug 23.

Chemotherapeutic agents and the skin: An update.

J Am Acad Dermatol. 2008 Apr;58(4):545-70. doi: 10.1016/j.jaad.2008.01.001.

Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.

J Clin Oncol. 2008 Aug 20;26(24):4047-8. doi: 10.1200/JCO.2008.18.3525.

[Cutaneous side effects of antiangiogenic agents].

Bull Cancer. 2007 Jul;94 Spec No:S260-4.

[Dermatologic side effects induced by new angiogenesis inhibitors].

Bull Cancer. 2011 Oct;98(10):1221-9. doi: 10.1684/bdc.2011.1457.

引用本文的文献

The effect of the RadioProtect cosmetic formulation on the skin of oncological patients treated with selected cytostatic drugs and ionizing radiation.

Postepy Dermatol Alergol. 2022 Feb;39(1):47-51. doi: 10.5114/ada.2022.113608. Epub 2022 Feb 28.

Multikinase inhibitor-associated hand-foot skin reaction as a predictor of outcomes in patients with hepatocellular carcinoma treated with sorafenib.

World J Gastroenterol. 2018 Jul 28;24(28):3155-3162. doi: 10.3748/wjg.v24.i28.3155.

Sorafenib-associated facial acneiform eruption.

Dermatol Ther (Heidelb). 2015 Mar;5(1):77-86. doi: 10.1007/s13555-014-0067-9. Epub 2014 Dec 25.

Cutaneous side effects associated with sunitinib: an analysis of 8 cases.

Int J Clin Pharm. 2012 Apr;34(2):286-9. doi: 10.1007/s11096-012-9615-5. Epub 2012 Mar 17.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

[Cutaneous side effects of sorafenib and sunitinib].

Ann Dermatol Venereol. 2008 Feb;135(2):148-53; quiz 147, 154. doi: 10.1016/j.annder.2007.12.006. Epub 2008 Feb 13.

A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.

J Natl Cancer Inst. 2008 Feb 20;100(4):282-4. doi: 10.1093/jnci/djm311. Epub 2008 Feb 12.

Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.

Br J Dermatol. 2009 Nov;161(5):1045-51. doi: 10.1111/j.1365-2133.2009.09290.x. Epub 2009 May 5.

[Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib].

Hautarzt. 2010 Aug;61(8):662-7. doi: 10.1007/s00105-010-1942-7.

Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.

Dermatol Ther. 2011 Jul-Aug;24(4):396-400. doi: 10.1111/j.1529-8019.2011.01435.x.

Risk of arterial thrombosis not increased by sorafenib or sunitinib.

J Clin Oncol. 2010 Oct 20;28(30):e619; author reply e620. doi: 10.1200/JCO.2010.31.0219. Epub 2010 Aug 23.

Chemotherapeutic agents and the skin: An update.

J Am Acad Dermatol. 2008 Apr;58(4):545-70. doi: 10.1016/j.jaad.2008.01.001.

Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.

J Clin Oncol. 2008 Aug 20;26(24):4047-8. doi: 10.1200/JCO.2008.18.3525.

[Cutaneous side effects of antiangiogenic agents].

Bull Cancer. 2007 Jul;94 Spec No:S260-4.

[Dermatologic side effects induced by new angiogenesis inhibitors].

Bull Cancer. 2011 Oct;98(10):1221-9. doi: 10.1684/bdc.2011.1457.

引用本文的文献

The effect of the RadioProtect cosmetic formulation on the skin of oncological patients treated with selected cytostatic drugs and ionizing radiation.

Postepy Dermatol Alergol. 2022 Feb;39(1):47-51. doi: 10.5114/ada.2022.113608. Epub 2022 Feb 28.

Multikinase inhibitor-associated hand-foot skin reaction as a predictor of outcomes in patients with hepatocellular carcinoma treated with sorafenib.

World J Gastroenterol. 2018 Jul 28;24(28):3155-3162. doi: 10.3748/wjg.v24.i28.3155.

Sorafenib-associated facial acneiform eruption.

Dermatol Ther (Heidelb). 2015 Mar;5(1):77-86. doi: 10.1007/s13555-014-0067-9. Epub 2014 Dec 25.

Cutaneous side effects associated with sunitinib: an analysis of 8 cases.

Int J Clin Pharm. 2012 Apr;34(2):286-9. doi: 10.1007/s11096-012-9615-5. Epub 2012 Mar 17.